<DOC>
	<DOCNO>NCT02586909</DOCNO>
	<brief_summary>This 12-month open-label study provide information regard long-term safety tolerability intepirdine ( RVT-101 ) subject Alzheimer 's disease complete double-blind , placebo-controlled , lead-in study RVT-101-3001 ( double-blind study ) .</brief_summary>
	<brief_title>12-Month Open-Label Extension Study Intepirdine ( RVT-101 ) Subjects With Alzheimer 's Disease : MINDSET Extension</brief_title>
	<detailed_description>This 12-month open-label study provide information regard long-term safety tolerability intepirdine ( RVT-101 ) subject Alzheimer 's disease complete double-blind , placebo-controlled , lead-in study RVT-101-3001 . Various background therapy , include acetylcholinesterase inhibitor memantine , allow .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Completed last ontreatment visit leadin study RVT1013001 Any clinically relevant concomitant disease , , opinion investigator , make subject unsuitable inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>RVT-101</keyword>
	<keyword>donepezil</keyword>
</DOC>